PPT-Dolutegravir + 2 NRTIs versus Darunavir + RTV + 2 NRTIs

FLAMINGO Dolutegravir 2 NRTIs versus Darunavir RTV 2 NRTIs FLAMINGO Study Design Source Clotet B et al Lancet 2014383222231 Dolutegravir TDFFTC or ABC3TC n 242 Darunavir Ritonavir . Learning Objectives. Understand when to switch to a second-line regimen. Know preferred second-line regimens for adults (including pregnant and breastfeeding women), adolescents, and children. Describe common drug resistance mutations and how they influence choosing a second-line regimen. 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared With Lopinavir/Ritonavir (LPV/RTV) Plus . 2 NRTIs in Second-Line Treatment: Interim Data From the DAWNING Study. Michael Aboud,. 1. Richard Kaplan,. Evidence-Based Approaches. Simply Speaking. ®. HIV “Essentials for Optimal Care of HIV Patients: Evidence-Based Approaches” is. Copyrighted 2018 by Practice Point Communications, unless otherwise noted.  All rights reserved.. 2 NRTIs in Treatment-Experienced. M97-765 Trial. Lopinavir. -RTV + . Nevirapine. + 2 NRTIs in Treatment-Experienced . M97-765: . Study Design. Source. : . Benson CA, et al. . J . Infect. . Dis. . 2002;185:599-607.. Lopinavir. -RTV in Treatment Experienced. TITAN Trial. Darunavir/. r . versus Lopinavir/r in Treatment-Experienced . TITAN. : Study Design. Source: . Madruga. JV, et al. Lancet. 2007;370:49-58. . Darunavir. Professor Francois Venter. Ezintsha, University of the Witwatersrand, Johannesburg, South Africa. Thanks to: The Ezintsha team, HE²RO, Sydney Rosen, Anna . Grismrud. , Phumla . Sinxabi. , Andrew Hill, Gary Maartens, Mohammed Ali, Mark Siedner, Elvin Geng, Aaloke Mody, Jeff Wing, Vince Marconi, Yogan Pillay, Liesel Page-Shipp, Thato Chidarikire. Virologically. Suppressed. OLE Trial. LPV-RTV + . 3TC vs. LPV. -RTV + 2 NRTIs. in . Virologically. Suppressed. OLE: . Study Design. Source: . Arribas. JR, et al. . Lancet Infect Dis. . 2015;15:. 785-92.. by Baseline NRTI Resistance . and Second-Line NRTI Use. Dannae. Brown,. 1. . Ruolan. Wang,. 2. Mark Underwood,. 2. Judy Hopking,. 3. Maria Claudia Nascimento,. 4. . Michael Aboud,. 4. . Jörg. E Duke. https://www.hiv.uw.edu/page/treatment/drugs. David . Spach’s. National HIV Curriculum. HIV . Virion. ssRNA. Reverse Transcriptase. Integrase. HIV . Virion. CD4 T Lymphocyte. Human CD4+ T cell. Prepared by:. Brian R. Wood, MD. David H. Spach, MD. Last Updated: January 28, 2021. Dolutegravir (. Tivicay. ) . INSTI. Tivicay. . [TIV-eh-kay]. Dolutegravir. Treatment Naïve. : 50 mg once daily with or without food. STEAL. Switch NRTIs to Tenofovir DF-Emtricitabine or Abacavir-Lamivudine. STEAL: Study Design. Source: . Martin A, et al. . Clin. Infect . Dis. 2009;49:1591. -1601. .. Study Design: STEAL. Background. DRIVE FORWARD. Doravirine. + 2 NRTIs vs. Darunavir + Ritonavir + 2 NRTIs. DRIVE FORWARD: Design. Source: Molina J-M, et al. Lancet HIV. 2018;5:e211-20.. Doravirine. + 2 NRTIs. (n = 385). Darunavir + RTV + 2 NRTIs. POWER 1 and 2. Darunavir. /. r versus other PIs in Treatment-Experienced . POWER 1 and 2. : Study Design. Source: . Clotet. B, et al. . Lancet. . 2007;369:. 1169-78.. Darunavir BID + RTV BID + OBR . RADAR Trial. Raltegravir. + Darunavir/r versus TDF-FTC + Darunavir/r. RADAR: Study Design. Source: . Bedimo. RJ, et al. . PLoS. One. 2014;9:e106221.. Darunavir QD + Ritonavir QD + Raltegravir BID .